Skip to main content
Apeloa Pharmaceutical Co.,Ltd. logo

Apeloa Pharmaceutical Co.,Ltd. — Investor Relations & Filings

Ticker · 000739 ISIN · CNE000000Q45 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,841 across all filing types
Latest filing 2020-03-11 Notice of Dividend Amou…
Country CN China
Listing Shenzhen Stock Exchange 000739

About Apeloa Pharmaceutical Co.,Ltd.

https://www.apeloa.com

Apeloa Pharmaceutical Co., Ltd. focuses on the research, development, manufacturing, and distribution of active pharmaceutical ingredients (APIs), intermediates, and finished dosage forms. The company operates three core business pillars: API production, Contract Development and Manufacturing Organization (CDMO) services, and finished drug products. Its therapeutic focus includes cardiovascular, anti-infective, anti-viral, and oncology treatments. Apeloa utilizes an integrated supply chain to deliver chemical and biological solutions to a global client base. The organization maintains compliance with international quality standards, including certifications from the FDA, EMA, and PMDA. Its CDMO services encompass the full product lifecycle, from process chemistry and analytical development to large-scale commercial manufacturing, supported by specialized technology platforms such as continuous flow chemistry and enzymatic synthesis.

Recent filings

Filing Released Lang Actions
独立董事关于对2019年度利润分配事项发表的独立意见
Notice of Dividend Amount Classification · 95% confidence The document is a statement from independent directors expressing their opinion on the 2019 annual profit distribution proposal. It references the profit distribution plan and the upcoming 2019 annual general meeting for approval. The content is focused on dividend distribution and the directors' approval, which aligns with a Notice of Dividend Amount filing. The document is short and specific to dividend details rather than a full report or announcement of a report publication.
2020-03-11 Chinese
独立董事关于对公司2020年度日常关联交易事项的独立意见
Audit Report / Information Classification · 90% confidence The document is an independent opinion from the independent directors of 普洛药业股份有限公司 regarding the company's 2020 annual related party transactions. It references regulatory guidelines from the China Securities Regulatory Commission and Shenzhen Stock Exchange listing rules, and discusses the fairness and legality of related party transactions. The document is a formal statement or opinion by the board's independent directors rather than a full audit report or annual report. It does not contain financial statements or detailed audit results, but rather an independent opinion on a specific governance matter related to related party transactions. This fits best under Audit Report / Information (AR), which includes standalone audit reports and applied accounting principles or internal governance opinions related to financial matters, excluding full annual reports. FY 2020
2020-03-11 Chinese
独立董事关于对公司2020年度日常关联交易事项的事前认可意见
Regulatory Filings Classification · 95% confidence The document is a statement from independent directors regarding the pre-approval of the company's 2020 annual related party transactions. It references regulatory guidelines and confirms the fairness and necessity of these transactions. The document is short (440 characters) and serves as an official opinion or announcement rather than a full report. It does not contain financial statements or detailed financial data. This fits best under Regulatory Filings (RNS), which covers miscellaneous regulatory announcements and confirmations that do not fit other categories.
2020-03-11 Chinese
独立董事提名人声明（二）
Board/Management Information Classification · 95% confidence The document is a public statement from the board of directors nominating an independent director candidate for the company's board. It details the nominee's qualifications, compliance with relevant laws and regulations, and independence criteria. There is no financial data, earnings information, or report publication mentioned. The content is related to board/management information, specifically about a nomination for a board position. Therefore, the document fits best under the category of Board/Management Information (MANG). The document length and detail support this classification with high confidence.
2020-03-11 Chinese
独立董事提名人声明（三）
Board/Management Information Classification · 100% confidence The document is a public statement from the board of directors nominating an independent director candidate for the company. It contains detailed declarations about the nominee's qualifications, compliance with relevant laws and regulations, and independence criteria. There are no financial statements, earnings data, or report attachments. The content focuses on board/management information, specifically the nomination of a board member. Therefore, this document fits the category of Board/Management Information (MANG). The document length is sufficient and the content is substantive, not merely an announcement or certification.
2020-03-11 Chinese
独立董事提名人声明（一）
Board/Management Information Classification · 95% confidence The document is a public statement from the board of directors nominating an independent director candidate for the company's board. It contains detailed declarations about the nominee's qualifications, compliance with relevant laws, regulations, and stock exchange rules, and confirms the nominee's independence and eligibility. There is no financial data, no discussion of financial results, no voting results, no legal proceedings, no capital changes, and no mention of an annual or interim report. The document is clearly related to board/management information, specifically about a nomination to the board. Therefore, the most appropriate classification is Board/Management Information (MANG). The document length (5558 characters) supports it being a full statement rather than a brief announcement or certification.
2020-03-11 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.